1. Home
  2. GSIT vs ALXO Comparison

GSIT vs ALXO Comparison

Compare GSIT & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GSI Technology

GSIT

GSI Technology

N/A

Current Price

$3.16

Market Cap

184.9M

Sector

Technology

ML Signal

N/A

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

N/A

Current Price

$1.14

Market Cap

172.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GSIT
ALXO
Founded
1995
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
184.9M
172.8M
IPO Year
2004
2020

Fundamental Metrics

Financial Performance
Metric
GSIT
ALXO
Price
$3.16
$1.14
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $4.60
AVG Volume (30 Days)
485.6K
★ 1.4M
Earning Date
11-05-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 26.36
EPS
N/A
★ N/A
Revenue
★ $25,122,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$12.85
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 22.44
N/A
52 Week Low
$2.97
$0.86
52 Week High
$13.00
$2.66

Technical Indicators

Market Signals
Indicator
GSIT
ALXO
Relative Strength Index (RSI) 29.48 44.49
Support Level N/A $1.03
Resistance Level $5.82 $1.34
Average True Range (ATR) 0.28 0.14
MACD -0.06 0.02
Stochastic Oscillator 11.90 29.49

Price Performance

Historical Comparison
GSIT
ALXO

About GSIT GSI Technology

GSI Technology Inc is a provider of semiconductor memory solutions. The company develops and markets high-performance memory products, including Very Fast static random access memory, or SRAM, that are incorporated in high-performance networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations, and network access equipment. It sells these products to original equipment manufacturers and customers including Nokia and customers segregated as-Contract manufacturers, Distribution and OEMs. In addition, it serves the ongoing needs of the military, aerospace and medical markets for high-performance SRAMs. It operates geographically in China, Singapore, the Netherlands, Germany, Rest of the world, and USA.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: